Anthem Biosciences Stock Screener | Share Price & Fundamental Analysis
ANTHEM
Biotechnology
Share Price NSE
₹774.30
▲
4.55 (0.59%)
Share Price BSE
₹773.45
▲
3.30 (0.43%)
As of April 28, 2026, the Anthem Biosciences share price (NSE: ANTHEM) is ₹774.30 on NSE and ₹773.45 on BSE, up 0.59% from the previous close, with shares trading between ₹756.95 and ₹785.90, and a 52-week range of ₹587.85–₹866.00.
Browse Anthem Biosciences financial data to support your investment research.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Anthem Biosciences Market Cap
₹36,215.42 Cr.
ANTHEM P/E Ratio (TTM)
73.37
Anthem Biosciences P/B Ratio
12.92
EPS (TTM)
₹8.07
Dividend Yield
-
Debt to Equity
0.08
ANTHEM 52 Week High
₹866.00
Anthem Biosciences 52 Week Low
₹587.85
Operating Margin
31.00%
Profit Margin
20.35%
ANTHEM Revenue (TTM)
₹457.00
EBITDA
₹165.00
Net Income
₹93.00
Total Assets
₹2,808.00
Total Equity
₹2,410.00
Anthem Biosciences Share Price History - Stock Screener Chart
Screen ANTHEM historical share price movements with interactive charts. Analyze price trends and patterns.
Anthem Biosciences Company Profile - Fundamental Screener
Screen Anthem Biosciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for ANTHEM shares.
Sector
Healthcare
Industry
Biotechnology
Sub-Sector
Biotechnology
Segment
E
ISIN
INE0CZ201020
Anthem Biosciences Balance Sheet Screener
Screen ANTHEM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total Assets | 2,808 | 2,398 | 2,015 | 1,619 | 1,034 | 787 |
| Current Assets | 1,737 | 1,482 | 1,323 | 1,098 | 616 | 403 |
| Fixed Assets | 705 | 483 | 449 | 329 | 361 | 306 |
| Liabilities | ||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 72 | 135 | 110 | 41 | 47 | 118 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||
| Total Equity | 2,410 | 1,925 | 1,741 | 1,355 | 702 | 422 |
| Share Capital | 112 | 112 | 114 | 9 | 9 | 8 |
| Reserves & Surplus | 2,298 | 1,813 | 1,627 | 1,346 | 693 | 414 |
Anthem Biosciences Income Statement Screener - Profit & Revenue Analysis
Screen Anthem Biosciences income statement and profit fundamentals.
Analyze ANTHEM quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Anthem Biosciences share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun |
|---|---|---|---|---|---|---|---|
| Revenue | 457 | 598 | 563 | 497 | 522 | 553 | 358 |
| Expenses | 291 | 332 | 349 | 288 | 338 | 330 | 218 |
| EBITDA | 165 | 266 | 214 | 209 | 184 | 223 | 140 |
| Operating Profit % | 31.00% | 40.00% | 35.00% | 40.00% | 32.00% | 37.00% | 36.00% |
| Depreciation | 35 | 34 | 27 | 30 | 20 | 20 | 19 |
| Interest | 0 | 3 | 2 | 1 | 3 | 4 | 4 |
| Profit Before Tax | 131 | 230 | 186 | 178 | 161 | 200 | 118 |
| Tax | 38 | 56 | 51 | 96 | 37 | 38 | 36 |
| Net Profit | 93 | 173 | 136 | 83 | 124 | 162 | 82 |
| EPS | 1.65 | 3.09 | 2.43 | 1.48 | 2.22 | 2.90 | 1.47 |
Anthem Biosciences Cash Flow Screener - Liquidity Fundamentals
Screen ANTHEM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March |
|---|---|---|---|---|---|---|
| Operating Activities | 418 | 140 | 306 | 333 | 278 | 166 |
| Investing Activities | -152 | -222 | -376 | -205 | -196 | -109 |
| Financing Activities | -134 | -77 | 64 | 181 | -63 | -48 |
| Net Cash Flow | 133 | -159 | -6 | 308 | 18 | 9 |
Anthem Biosciences Shareholding Pattern Screener
See Anthem Biosciences shareholding pattern with promoter, FII, and DII holdings.
Check Anthem Biosciences promoter holding and ownership changes for ANTHEM on TickJournal.
| Item | 2025-Jul | 2025-Sept | 2025-Dec | 2024-Dec |
|---|---|---|---|---|
| Promoter Holding | 76.88% | 74.69% | 74.69% | 77.23% |
| FII Holding | 0.00% | 1.67% | 1.36% | 0.00% |
| DII Holding | 0.00% | 7.22% | 7.60% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 0.00% | 9.61% | 9.60% | 0.00% |
| Other Holding | 23.12% | 6.81% | 6.74% | 22.77% |
| Shareholder Count | 761 | 217,681 | 199,492 | 16 |
Anthem Biosciences Share Dividend Screener - Share Yield Analysis
Check Anthem Biosciences dividend history with payout and yield data.
View Anthem Biosciences dividend details including ex-dates and amounts for ANTHEM stock.
Anthem Biosciences Stock Index Membership
See which indices include Anthem Biosciences stock.
Check ANTHEM index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Anthem Biosciences Market Events Screener - Corporate Actions
Get Anthem Biosciences corporate actions including splits, bonuses, and buybacks.
Check Anthem Biosciences stock events that may affect ANTHEM share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-02-05 | 2026-02-05 | Quarterly Result Announcement | NA | -0.59% |
| 2025-11-08 | 2025-11-08 | Quarterly Result Announcement | NA | -6.08% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -0.83% |
Anthem Biosciences Competitors Screener - Peer Comparison
Screen ANTHEM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Anthem Biosciences | 36,215 | 73.37 | 1,930 | 30.15% | 451 | 44.40 |
| Advanced Enzyme Tech | 3,051 | 19.73 | 670 | 1.44% | 134 | 37.55 |
| Genesis IBRC | 131 | -568.61 | 4 | % | 0 | 65.77 |
| Vivo Bio Tech | 57 | 12.10 | 52 | 13.19% | 7 | 46.95 |
| Shree Ganesh Bio-Tech | 23 | -56.00 | 24 | 14.55% | 0 | 45.82 |
| Genomic Valley Biotech | 9 | -189.53 | 1 | 300.00% | 0 | 60.12 |
Anthem Biosciences Company Announcements - News Screener
Screen ANTHEM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-04-21 | Announcement under Regulation 30 (LODR)-Cessation | - |
| 2026-02-23 | Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI LODR Regulations) | - |
| 2026-02-09 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-02-06 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-05 | Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised) | - |
| 2026-02-05 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-02-05 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-02-05 | Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised) | - |
| 2026-02-05 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-02-05 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-02-05 | Financial Results For The Quarter And Nine Months Ended December 31 2025 | - |
| 2026-02-05 | Board Meeting Outcome for Outcome Of The Board Meeting Held On Thursday February 05 2026 | - |
| 2026-01-27 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-01-27 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-01-27 | Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025 | - |
| 2026-01-07 | Compliance Certificate Under Regulation 74(5) Of SEBI (DP) Regulations 2018 | - |
| 2026-01-07 | Intimation Under Regulation 30 Of SEBI LODR Regulations With Reference To Issuance Of Corporate Guarantee | - |
| 2025-12-29 | Closure of Trading Window | - |
| 2025-12-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |